EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Butyrylcholinesterase (BChE) downregulation in taxane resistance: implications for prostate cancer

Buse Cevatemre iD, Arda Işiklar iD, İpek Bulut iD, Ezgi Karyemez iD, Hamzah Syed iD, Ceyda Açilan iD

Turkish Journal of Biology · 26.06.2025 · 49 (3) · 261-272

DOI: 10.55730/1300-0152.2743 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Biology, online erschienen am 26.06.2025. Verfasst von Buse Cevatemre und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Biology, Faculty of Medicine, Koç University, İstanbul, Turkiye. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aim: Despite advancements in chemotherapeutic strategies, drug resistance remains a major barrier to effective cancer treatment. While primary prostate cancers (PC) can be treated with surgery and radiotherapy, treatment options for recurrent PC are limited. Upon progression to the castration-resistant (CR) phase, therapies rely on taxanes (chemotherapeutic drugs) like docetaxel (Dtx) and cabazitaxel (Cbz); however, resistance to taxanes is common in CRPC, highlighting the importance of identifying underlying molecular mechanisms or targets in resistant cells.Materials and methods: In transcriptome (RNA sequencing) analyses comparing taxane-resistant PC cells (resistant to both Dtx and Cbz) with parental (nonresistant, sensitive) cells, butyrylcholinesterase (BChE) was identified as the most significantly downregulated gene. Although low serum BChE levels have been documented in various cancers, its role in chemotherapy resistance remains unclear. To address this gap, we validated its expression in taxane-resistant CRPC lines and manipulated BChE levels in both parental and resistant cells via lentiviral overexpression or depletion using shRNA and gRNA (CRISPR-Cas9), to assess its impact on taxane resistance.

Results

BChE suppression in parental CRPC cells conferred resistance, whereas its overexpression in taxane-resistant cells was insufficient to resensitize them. Analysis of publicly available databases showed reduced BChE mRNA levels in patient samples across various cancers, including PC. Additionally, The Cancer Genome Atlas (TCGA) analyses identified BChE as a significant posttreatment neoplasm marker in PC.

Conclusion

Our study confirmed the downregulation of BChE in taxane-resistant CRPC cell models and established its role in conferring resistance when depleted in parental CRPC cells, highlighting its association with taxane resistance. Additionally, the identification of BChE as a posttreatment neoplasm marker, derived from data mining analyses, suggests it might serve as a biomarker for tracking disease progression in PC.

Schlagwörter

Stichwörter der Autor:innen

Prostate cancerchemotherapydrug resistancetaxane

Autor:innen und Institutionen

  • Division of Medical Biology, Faculty of Medicine, Koç University, İstanbul, Turkiye.
  • Research Center for Translational Medicine, Koç University, İstanbul, Turkiye.
  • Graduate School of Health Sciences, Koç University, İstanbul, Turkiye.

ORCID-Profile: Buse Cevatemre, Arda Işiklar, İpek Bulut, Ezgi Karyemez, Hamzah Syed, Ceyda Açilan

Zitieren

APA

Cevatemre, B., Işiklar, A., Bulut, İ., Karyemez, E., Syed, H., & Açilan, C. (2025). Butyrylcholinesterase (BChE) downregulation in taxane resistance: implications for prostate cancer. Turkish Journal of Biology, 49(3), 261-272. https://doi.org/10.55730/1300-0152.2743

Vancouver

Cevatemre B, Işiklar A, Bulut İ, Karyemez E, Syed H, Açilan C. Butyrylcholinesterase (BChE) downregulation in taxane resistance: implications for prostate cancer. Turkish Journal of Biology. 2025;49(3):261-272. doi:10.55730/1300-0152.2743

BibTeX
@article{Cevatemre2025,
  author = {Cevatemre, Buse and Işiklar, Arda and Bulut, İpek and Karyemez, Ezgi and Syed, Hamzah and Açilan, Ceyda},
  title = {Butyrylcholinesterase (BChE) downregulation in taxane resistance: implications for prostate cancer},
  journal = {Turkish Journal of Biology},
  year = {2025},
  volume = {49},
  number = {3},
  pages = {261--272},
  doi = {10.55730/1300-0152.2743}
}
Kostenlos starten →